• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Flu jab "may cut" stroke risk by a quarter
ConclusionThis research finds that, overall, having the flu vaccine reduced the risk of a person experiencing a stroke by about 25%. The reduction in risk seemed to be greatest within the first three months of vaccination, but remained for up to 12 months.  However, the effect lasted only if the vaccine was given early in the flu season (September to mid-November); giving the vaccine late in the flu season (mid-November to February) was not associated with significantly reduced risk.The research benefits from using data coded within the General Practice Research Database for England and Wales for almost 50,000 people with...
Source: NHS News Feed - February 21, 2014 Category: Consumer Health News Tags: Heart/lungs Neurology Older people Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news